BRL Medicine

BRL Medicine Inc. is committed to becoming a globally leading cell and gene therapy company in the era of new commercial civilization. BRL Medicine's mission is "to lead innovation with gene editing technology, develop breakthrough therapies, and benefit all humanity." Relying on its self-developed center and the "Shanghai Gene Editing and Cell Therapy Research Center" co-built with universities, it has generated more than 100 patent achievements so far. Five projects are conducting investigator-initiated clinical trials in eight well-known hospitals, three projects have been approved for IND and officially entered the registration clinical trial stage, and several other projects are in the IND application stage. Among them, gene editing treatment for β-thalassemia, non-viral PD1 targeted integration CAR-T, and UCART projects have achieved excellent clinical results, demonstrating global leadership, and multiple academic papers have been published in prestigious academic journals such as Nature, Nature Medicine, and Nature Biotechnology. BRL Medicine has established five proprietary technology platforms: a gene editing technology innovation platform, a hematopoietic stem cell platform, a non-viral targeted integration CAR-T platform, a universal cell platform, and an enhanced T-cell platform. It owns a 7,000-square-meter GMP pilot base and a nearly 200-person operations team, effectively ensuring that innovative research results can be quickly transformed and applied. BRL Medicine continuously drives rapid updates and iterations of its R&D products based on patient needs and clinical feedback. Upholding an attitude of openness, sharing, and win-win cooperation, BRL Medicine accelerates the transformation and implementation of innovative drugs together with global innovative biopharmaceutical ecosystem enterprises, benefiting patients with genetic diseases, malignant tumors, and autoimmune diseases worldwide!